Closed · RFA-FD-14-004 · CFDA 93.103 · Discretionary

Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$200K-$225K
Award range
Closed
Status
June 16, 2014
Close date
4
Expected awards

The verdict

Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24) is a closed discretionary listing from Food and Drug Administration that offered $200,000 -- $225,000 across 4 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$200K-$225K
award range
Closed
application status
4
expected awards
93.103
CFDA program

Archived opportunity record

Data Concepts and Terminology Standards for C… is closed (last close June 16, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 16, 2014

Posted Apr 29 Closes Jun 16

Est. Total Funding

$1,000,000

Expected Awards

4

Instrument

Cooperative Agreement

Description

The Center for Drug Evaluation and Research (CDER) receives a vast and growing amount of data in a variety of regulatory submissions from a multitude of sources and in a variety of formats. This wealth of data holds great potential to advance CDER’s regulatory and scientific work, but the present lack of standardized data creates significant challenges to realizing that potential. The volume and complexity of drug-related information submitted to CDER for regulatory review is creating significant challenges to the Center’s ability to efficiently and effectively perform its critical public health mission.The lack of standardized data affects CDER’s review processes by curtailing a reviewer’s ability to perform integral tasks such as rapid acquisition, analysis, storage and reporting of regulatory data. Improved data quality, accessibility and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions and address late-emerging issues. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. This will enhance the Center’s performance across key drug regulatory functions and ongoing business operations, including pre-market review, post-market safety, oversight of drug quality, and oversight of drug promotion.In accordance with the Office of Management and Budget (OMB) Circular A-119, the FDA will: use voluntary, consensus-based standards development processes in place of government unique standards unless such standards are inconsistent with law or otherwise impractical; advocate to align these standards with existing health information technology initiatives, laws, regulations, and mandates; and promote coordination with other standards currently in use. The projects selected under this funding opportunity must adhere to these principles.OVERARCHING PROGRAM GOAL:The CDER Data Standards Program's goals are: Support open, consensus-based data standards development Maintain and promote a well-defined data standards governance function Promote the electronic submission of regulatory data using established standards Optimize the regulatory review process to fully leverage data conformed to standards PROGRAM PRIORITIES:The Food and Drug Administration is announcing the availability of cooperative agreements for the development of data concepts and terminology standards to support human drug development and evaluation. The primary objective is to support the development of non-proprietary, consensus-based data standards for use in clinical studies of human drugs and biologics. Projects may focus on the identification of solutions to data standards development and their challenges in areas, such as general clinical and nonclinical study data, specific therapeutic areas, as well as other sections of the regulatory submission (e.g., quality / Chemistry, Manufacturing, and Controls (CMC)).DESCRIPTION:The application must include:An overall program plan describing the approach, process to be used in developing the selected area for standardization, any specific technologies to be utilized and experience with those technologies, and deliverables A method (e.g., Gantt chart) to plan and track progress toward specific deliverables under this award for the purpose of reporting the status to the FDA and its stakeholders. At a minimum, information reported should include a listing of interim steps necessary to complete a given deliverable, the timeline for completing those tasks, and a report of any issues in meeting those established deadlines. Definition of scope to be addressed (e.g., use case) during the project period Description of the result (concept, terminology, domain, therapeutic area) to be developed in the application (e.g., completed implementation guide) Description of the coordination/collaboration (to achieve consensus) needed to address the area of standardization including by not limited to: engagement of subject matter experts, organizations, standards development organizations, affected stakeholdersHow the standard being addressed aligns with currently available standards and approach to making the standard publically available A description of the experience of the principal investigators (PI), who is/are the Program Director (PD), should be described, together with his/her/their involvement in the projects. It is expected that PI(s) should have experience with data standards development as the PI(s) have the ultimate responsibility for the successful outcomes of the projects Specific Areas of Research Interest: FDA/CDER is specifically interested in projects to develop standardized clinical research concepts and terminology for therapeutic areas with significant drug development pipeline activity, emerging or complex analytical challenges, and/or are of significant public health concern. The list of therapeutic areas with current status is available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm287408.htm.

Wide-open applicant board · 15 Grants.gov doors

Data Concepts and Terminology Standards for C… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Income Security and Social Services · Science and Technology / R&D (HL;IS;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 240-402-7565

What to do next

Data Concepts and Terminology Standards for C… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants